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Levamisole enhances global and differential leukocyte numbers in peripheral blood of
dogs with ehrlichiosis
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Abstract: Ehrlichiosis is a disease caused by Ehrlichia, a genus of obligatory intracellular bacteria that parasitize leukocytes and provoke
several hematological alterations. In this work, we investigated the effect of levamisole associated with doxycycline on peripheral
leukocytes in dogs PCR-positive for ehrlichial DNA. Twenty-one Ehrlichia-infected dogs were randomly distributed in 2 groups: a
control group (n = 10) and a levamisole-treated group (n = 11). Blood samples were collected from each animal for hematological and
DNA analysis both before initiating the experiment and 5 days later. All dogs were treated with doxycycline (10 mg/kg body weight),
cimetidine (5 mg/kg of body weight), and fluid therapy for 5 consecutive days. In addition to receiving antibiotic therapy, the levamisoletreated dogs received a single subcutaneous injection (1 mg/kg body weight) of levamisole on the first day of the experiment. The results
show that levamisole associated with doxycycline significantly enhanced global leukocyte, lymphocyte, and monocyte numbers in the
peripheral blood of dogs with ehrlichiosis. Those data suggest that the combination of doxycycline with levamisole may improve canine
ehrlichiosis treatment through impairment of leukopenia, which is not controlled by antibiotic therapy alone.
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1. Introduction
Ehrlichiosis is an emergent tick-borne bacterial disease
that affects several animal species, including livestock
and companion animals (1). Moreover, ehrlichiosis is
an important public health problem since Ehrlichia
canis and E. chaffeensis are causes of human monocytic
ehrlichiosis (2–4). E. canis is the primary agent of
canine monocytic ehrlichiosis (5) but E. canis and
E. ewingii have been identified as causes of canine
ehrlichiosis in Brazil (6,7). Based on experimental
infection of dogs with E. canis, canine monocytic
ehrlichiosis is divided into acute, subclinical, and
chronic phases (8–12). Accordingly, in the acute phase,
leukopenia, thrombocytopenia, fever, anorexia, and
depression are observed. During the subclinical phase,
clinical signs are minimal, but leukopenia, anemia,
and thrombocytopenia can still be observed (13).
The chronic phase of canine monocytic ehrlichiosis
may be severe or mild with recurrent clinical and
* Correspondence: albuquerqued@yahoo.com

hematological signs that include lymphocytosis,
monocytosis, pancytopenia, hemorrhage, and weight
loss (8,10,14–18). Ehrlichial diseases are remarkable for
their uniform susceptibility to doxycycline but failures
to treat Ehrlichia-infected dogs have unfortunate
and sometimes tragic outcomes, mainly due to
hematological alterations that are not controlled by
antibiotic therapy (19). Since ehrlichiosis causes severe
abnormalities in the immune response of dogs (12), we
reasoned that treatment of naturally Ehrlichia-infected
dogs would be improved through up-regulation of the
immune response with levamisole, which is a potential
Th1-biased compound (20,21). To test this hypothesis,
we evaluated the effects of levamisole on the global
and differential number of peripheral leukocytes in
dogs with ehrlichiosis and showed that combining
doxycycline therapy with levamisole significantly
increased peripheral leukocytes and promoted a better
recovery based on several clinical signs.
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2. Materials and methods
2.1. Animals
Twenty-one Ehrlichia-infected dogs were randomly
distributed in 2 groups: a control group (n = 10) and a
levamisole-treated group (n = 11). This study included
female and male dogs of several breeds and ages that
were naturally infected with Ehrlichia spp. and were PCRpositive for ehrlichial DNA. Dogs that had recently received
a blood transfusion or were taking corticosteroids, as well
as those that were newborn, pregnant, breast-feeding, or
had any concomitant disease, were excluded from this
study. The experiment was conducted in accordance with
the institutional guidelines for animal welfare (protocol
#23108.021390/08-4).
2.2. Polymerase chain reaction (PCR)
Blood samples from dogs suspected of having clinical
ehrlichiosis were collected into plastic tubes containing
EDTA and a DNA extraction of whole blood was
carried out as previously described (22). The DNA
samples were initially processed using a PCR protocol
designed to amplify a 409-bp fragment of the dsb gene
of the genus Ehrlichia (23) using primers 330 forward (5’
GATGATGTCTGAAGATATGAAACAAAT 3’) and 728
reverse (5’ CTGCTCGTCTATTTTACTTCTTAAAGT 3)’.
Ehrlichia spp. DNA was detected in the peripheral blood
of dogs by using PCR amplification of a genus-specific
disulfide bond formation protein (23). PCR products were
resolved on 2% agarose gels and visualized using ethidium
bromide staining under UV transillumination. DNA from
a São Paulo strain of E. canis was used as the positive
control and water as the negative control.
2.3. Clinical assessment
Before initiating the experiment, dogs that were PCRpositive for ehrlichial DNA were assessed for clinical
signs such as lethargy, icteric mucous membranes,
splenomegaly, abdominal petechiae, lymphadenopathy,
anorexia, epistaxis, uveitis, and hydration condition. A
rectal temperature check was also performed, and pulse
and respiration were noted. Infected dogs included in this
study were held in the veterinary hospital of the University
of Cuiabá (UNIC, Cuiabá, MT, Brazil) for 5 days. During
the experiment, all dogs were monitored daily for signs of
illness and at the end of the treatment they were clinically
assessed again.
2.4. Hematologic evaluations
Peripheral blood was collected in sterile tubes containing
anticoagulant (EDTA) and assessed for global leukocyte
and erythrocytes counts using a Neubauer chamber and
differential blood cells and platelets on smears stained with
a fast panoptic stain (Laboclin®).
2.5. Treatment
The antibiotic therapy for Ehrlichia-infected dogs consisted
of doxycycline (Adoxa®) (10 mg/kg of body weight, orally)
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and cimetidine (Tagamet®) (5 mg/kg of body weight,
intravenously). Both medicines were administered once a
day for 5 consecutive days. When it was required, animals
also received fluid therapy. Before starting the treatment,
11 Ehrlichia-infected dogs also received a subcutaneous
injection of levamisole (Ripercol® L Solution; 1 mg/kg of
body weight) and the other 10 Ehrlichia-infected dogs were
subcutaneously injected with saline as the control.
2.6. Statistical analysis
An experimental model with 2 groups and at least 10
repetitions was used. The results obtained from the
hematological evaluations were treated with one-way
analysis of variance (ANOVA) followed by the Tukey test
using SAEG 5.0 software. P ≤ 0.05 was considered significant.
3. Results
3.1. Effect of levamisole on the global number of leukocytes
in dogs with ehrlichiosis
To verify whether levamisole would increase the global
number of leukocytes in dogs naturally infected with
Ehrlichia, blood samples were collected from each animal
before starting the treatment and after a 5-day doxycycline
therapy associated or not associated with levamisole, and
they were assessed for complete blood counts as described in
Section 2. As shown in Table 1, at the end of the experiment,
the levamisole-treated dogs reached significantly higher
levels of global leukocytes than the control animals (P =
0.04). It should be noted that before initiating the treatment,
1 dog of the control group and 2 animals of the levamisoletreated group had leukopenia, but there was no statistical
difference between the 2 groups (P = 0.1). Notably, by the
end of the experiment, those 3 animals had recovered
from leukopenia, but 3 other dogs of the control group
and 1 animal of the levamisole-treated group developed
leukopenia (data not shown).
3.2. Evaluation of the levamisole effect on subsets of
leukocytes in dogs naturally infected with Ehrlichia
As levamisole significantly augmented the global number
of leukocytes in dogs with ehrlichiosis, we then evaluated
leukocyte subsets on blood smears stained with the fast
panoptic stain. At the end of the experiment, the levamisoletreated dogs reached significantly higher counts of
lymphocytes compared to the control group (Table 1; P =
0.02). Before initiating the experiment, 8 out of 11 animals
of the levamisole-treated group and 3 out of 10 dogs of the
control group had lymphopenia, but that difference was not
significant (P = 0.34). At the end of the treatment, only 1 dog
of the levamisole-treated group did not return to normal
values of lymphocytes, while 5 animals of the control group
were lymphopenic (data not shown). Our results corroborate
data from Sousa (24), who showed that levamisole increases
the global levels of leukocytes and absolute numbers of
lymphocytes in mice.
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Table 1. Total and subsets of peripheral leukocytes in dogs with ehrlichiosis. Different superscript letters indicate
statistical differences.

Peripheral leukocytes (×106/mL)

Control group

Levamisole-treated group

Day 0

Day 5

Day 0

Total leukocytes

5.200 ± 970

8.450 ± 1.374

4.327 ± 1.228

Lymphocytes

1.104 ± 176

1.705 ± 346

957 ± 433a

2.793 ± 1.229b

Mature neutrophils

4.109 ± 1.121

5.924 ± 1.306

3.312 ± 1.450

7.419 ± 2.555

Immature neutrophils

40 ± 41

123 ± 59

55 ± 61a

63 ± 69b

Monocytes

58 ± 61

132 ± 36

41 ± 35

219 ± 99b

3.3. Evaluation of the levamisole efficacy on erythrocyte
and platelet counts and hematocrit values in dogs
naturally infected with Ehrlichia
It is well known that besides causing several abnormalities
in white cells, Ehrlichia also provokes anemia and
thrombocytopenia in infected dogs (19). Therefore, in this
work we evaluated erythrocyte and platelet counts and
hematocrit values in dogs with ehrlichiosis. Before starting
the experiment, 7 out of 10 dogs of the control group had
anemia, and after 5 days of doxycycline therapy, 3 dogs

a

10.627 ± 2.757b

remained anemic (Figure). Before initiating the treatment,
7 out of 10 dogs of the control group also had reduced
levels of hematocrit, and 2 of them remained with low
values 5 days later (data not shown). At the beginning of
the experiment, 8 out of 11 of the levamisole-treated group
were anemic (data not shown). Five days later, only 3 of
the 11 dogs that received levamisole did not recover from
the anemia. At day 0, 9 dogs that would receive levamisole
had low hematocrit values, and at the end of the treatment,
only 2 animals of the levamisole-treated group did not
return to normal hematocrit values. Considering anemia
and hematocrit values, there was no statistical difference
between the levamisole-treated animals and the control
dogs (P = 0.4). Since Ehrlichia also decreases platelets
counts in infected-dogs, we also evaluated the numbers of
platelets. Before starting the therapy, all of the dogs with
ehrlichiosis had reduced platelets counts (data not shown).
However, the dogs that would receive levamisole had
significantly lower numbers of platelets than the control
animals (P = 0.001). At the end of the experiment, 5 dogs
of the control group and 8 animals of the levamisoletreated group continued to have low numbers of platelets
(data not shown).
8
Erythrocytes × 10 6/μ L

As shown in Table 1, after a 5-day doxycycline therapy,
all of the levamisole-treated dogs returned to normal
value ranges of neutrophils and only 1 dog of the control
group remained neutropenic, but that difference was not
significant (P = 0.1). Notably, before starting the treatment,
5 out of 10 dogs of the control group and 7 animals of the
levamisole-treated group were neutropenic. However, that
difference was not statistically significant (P = 0.18). Even
though levamisole associated with doxycycline did not
significantly enhance the number of mature neutrophils,
we evaluated the number of peripheral immature
neutrophils and observed that the levamisole-treated dogs
had significantly lower counts of peripheral immature
neutrophils than the control animals (Table 1; P = 0.05).
Therefore, we postulate that levamisole may stimulate the
immune response, which in turn would impede the massive
neutrophil deaths caused by Ehrlichia, and consequently a
lower number of immature neutrophils would be output
from the bone marrow.
In this work, we also analyzed the number of
monocytes on blood smears from dogs naturally infected
with Ehrlichia. The data presented in Table 1 show that
5 days after treatment, the levamisole-treated animals
reached significantly higher numbers of monocytes
than the control dogs (P = 0.02). It should be noted that
before starting the treatment, there were no animals with
monocytosis. Instead, 8 out of 10 dogs of the control
group and all animals of the levamisole-treated group had
decreased numbers of monocytes.

Day 5
a

b

Day 0
Day 5

6

a

4
2
0

Control group

Levamisole-treated group

Figure. Levamisole’s effect on erythrocytes in dogs naturally
infected with Ehrlichia. Peripheral blood was collected from
control animals and from levamisole-treated dogs and assessed
for erythrocytes counts using a Neubauer chamber. Data are
shown as mean ± SD.
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3.4. Clinical signs of dogs in which ehrlichial DNA was
detected by PCR
The animals included in this study entered the veterinary
hospital of the University of Cuiabá (UNIC) presenting
the following clinical signs: apathy, anorexia, abdominal
petechiae, dehydration, icteric mucous membranes,
lymphadenopathy, and splenomegaly (Table 2). Some
animals also presented epistaxis, uveitis, and fever (data
not shown). PCR amplification of peripheral blood
samples detected ehrlichial DNA in 21 out of 40 dogs
clinically suspected of having ehrlichiosis. On day 5, when
the last data were recorded, all levamisole-treated dogs had
recovered from anorexia and abdominal petechiae while
some control animals were still presenting those clinical
signs (Table 2).
4. Discussion
Levamisole, a synthetic phenylimidazothiazole, is a potent
anthelmintic agent that was introduced in 1966 (25) and
has been used to improve the treatment of colon cancer
(26). Current studies have been focused on the effect of
levamisole on the immune response as a potential Th1biased compound (20,21). Regarding levamisole as a Th1enhancing agent, it was useful in the treatment of leprosy
based on an Indian clinical trial (27) and has been used
to treat and prevent atopic diseases in the mouse model
(28). In this work, we evaluated the effect of levamisole
associated with doxycycline on peripheral leukocytes in
dogs PCR-positive for ehrlichial DNA and showed that
doxycycline plus levamisole significantly enhanced global
leukocyte, lymphocyte, and monocyte numbers in the
peripheral blood of dogs naturally infected with Ehrlichia.
The mechanism(s) by which levamisole enhances peripheral
leukocytes in dogs with ehrlichiosis was not determined,
but one could postulated that levamisole may reinforce the

Ehrlichia-lipopolysaccharide effect on macrophages and
dendritic cells to secrete IL-12 to help T cell activation. As
is well known, IL-12 promotes Th1 immune response by
inducing the production of large amounts of INF-γ by T
and NK cells (29). The hypothesis that levamisole acts on
the macrophages and dendritic cells of dogs is supported
by a previous report showing that levamisole increased
the production of IL-10 and IL-12 by human monocytederived dendritic cells (20). As Ehrlichia are intracellular
bacteria that mainly infect the monocytes/macrophage
phagocytic system, an immune response polarized toward
the Th1 profile would be more protective for dogs with
ehrlichiosis.
As shown, overall levamisole increases global leukocyte,
lymphocyte, and monocyte numbers in the peripheral
blood of dogs with ehrlichiosis; however, one dog of the
levamisole-treated group developed leukopenia during the
treatment. Because of that, we postulate that other doses
of levamisole and different frequencies of administration
of this medicine should be tested to standardize a protocol
that could be used in association with antibiotic therapy for
successful treatment of ehrlichiosis in dogs. Independent
of the remarkable susceptibility of Ehrlichia to doxycycline,
3 dogs of the control group developed leukopenia during
the treatment. These results reinforce the postulation that
leukopenia may progressively continue until the potential
elimination of the Ehrlichia infection in dogs.
Levamisole associated with doxycycline did not alter
the number of mature neutrophils. Nevertheless, our
results are in agreement with previous studies carried out
in caprines that reported a lack of effect of levamisole on the
absolute number of mature neutrophils (30). However, the
dogs treated with doxycycline associated with levamisole
had fewer immature neutrophils compared to the control
group. The mechanism(s) by which levamisole enhances

Table 2. Effect of levamisole on clinical signs in dogs with ehrlichiosis.

Clinical signs
Apathy
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Control group

Levamisole-treated group

Day 0

Day 5

Day 0

Day 5

9/10

4/10

9/11

3/11

Pallid mucous

2/10

0/10

3/11

0/11

Splenomegaly

5/10

3/10

7/11

3/11

Petechial hemorrhage

2/10

1/10

4/11

0/11

Lymphadenopathy

5/10

3/10

7/11

2/11

Anorexia

7/10

3/10

4/11

0/11

Epitasis

3/10

0/10

1/11

0/11

Uveitis

0/10

0/10

1/11

0/11

Dehydration

3/10

0/10

3/11

0/11
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lymphocyte and monocyte numbers and decreases immature
neutrophils in dogs with ehrlichiosis was not studied but
we hypothesize that levamisole may activate lymphocytes,
which via cytokine production would activate monocytes
and macrophages for the elimination of Ehrlichia, which in
turn would prevent neutrophils from dying.
According to our data, it seems that levamisole
associated with doxycycline does not change the usual
profile of anemia, platelet counts, and hematocrit values
observed in Ehrlichia-infected dogs. It has been shown that
Ehrlichia-infected dogs slowly return to normal numbers
of platelets from the seventh week after infection (31).
The slow recovery from thrombocytopenia is attributed at
least in part to Ehrlichia activation of a factor that inhibits
platelet migration from the bone morrow to the peripheral
blood, faster platelet death, and production of antibodies
against platelets (19).

Besides increasing peripheral leukocytes, levamisole
also improved some clinical signs in dogs with ehrlichiosis.
As far as we know, we are showing for the first time that
levamisole enhances peripheral leukocytes and improves
the antibiotic treatment of dogs with ehrlichiosis. In general,
our data indicate that using levamisole associated with
doxycycline to treat dogs with ehrlichiosis may improve
animals’ immune response, which in turn would contribute
to a better clinical recuperation from ehrlichiosis.
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